We describe a simplified isocratic "high-performance" liquid-chromatographic method for measuring a new immunosuppressive drug, cyclosporin A, in biological fluids with use of its analogs cyclosporin C and cyclosporin D as internal standards. The method is reproducible and accurate and appears to be specific for cyclosporin A; the detection limit is 31 .tg/L. The chromatographic measurements of the concentration of cyclosporin A in serum of patients receiving the drug were invariably lower than those by radioimmunoassay and the difference became more pronounced the greater the period of time after dosing. Because measurements of cyclosporin A in serum standards were almost identical with both techniques, the differences between the two sets of results for patients' samples suggests that the radioimmunoassay is nonspecific and measures metabolites of cyclosporin A.
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Materials and Methods
The analytical equipment consisted of a "high-performance" liquid chromatographic system (Waters Scientific, Ltd., Mississauga, Ontario, Canada) controlled by a M-660 solvent programmer. Injection was either manual or by an automatic injection system (Waters Intelligent Sample Processor, WISP-710B). The column was a Beckman UItrasphere-Octyl 5-am particle size reversed-phase column, 25 cm X 4.6 mm, maintained at 72 #{176}C in a water bath. The detection system was a Waters M-450 variable wavelength detector. Peaks were recorded and integrated with a Waters data module.
Reagents consisted of glass-distilled diethyl ether, HPLC-grade acetonitrile and methanol, cp hydrochloric acid, anhydrous sodium hydroxide, granular purified ammonium sulfate, and cyclosporins A, C, and D (donations from Sandoz Ltd., Basle, Switzerland).
Water was further purified by passing filtered, de-ionized water through a C-18 Sep-Pak (Waters). 
Chromatographic Conditions
The mobile phase consisted of acetonitrile/methanol/water (47/20/33 by vol) and its flow rate was 1.5 mL/min, column pressure 1200 psi (8274 kPa). The detector was set at 210 nm and 0.02 attenuation units full scale. For optimal peak integration with the data module, peak width setting was 45s and 
Results

Examples
of actual chromatograms are presented in Figure   1 . Figure 1A We checked for possible interference from endogenous and exogenous substances but saw no peaks that co-eluted with CyA, CyC, or CyD in the numerous pooled plasma samples used for preparing standards, in plasma samples from patients not receiving CyA, in plasma samples from patients receiving other drugs, or in plasma samples deliberately supplemented with various other drugs (analgesics, sedative-hypnotics, antibiotics, corticosteroids, anti-arrhythmic agents, bronchodilator drugs, antidepressants, psychotropic drugs, and anti-hypertensive drugs, including the beta-blockers and diuretics). However, plasma samples of two patients receiving CyA showed peaks slightly before the CyD peak in virtually all their samples, which interfered with proper evaluation of the CyD peak. We have not observed any interferencewith the CyC peak.
Comparison of HPLC with RIA Measurements We compared RIA of pure CyA in plasma with HPLC measurements. In addition, we compared RIA and HPLC measurements in plasma samples taken 2 and 12 h after oral drug administration.
Examples of these comparisons are presented in Figures 3-5 .
Over the range of concentrations studied, measurements of CyA concentration in plasma samples to which pure drug had been added were essentially identical by either RIA or the HPLC technique, although HPLC measurements of pure drug in plasma tended to be slightly greater than RIA measurements of pure drug (Figures 3 and 4) . However, HPLC measurements of CyA concentration in plasma of patients who had actually received the drug were invariably less than those by RIA. Moreover, there was considerable variation in the relationship between HPLC and RIA measurements at each of the two study times, both within-patient and between-patients. Figure 3 presents the comparison of plasma concentrations of CyA measured by both RIA and HPLC techniques. The samples were obtained two to 27 days after renal transplantation in a 33-year-old man. His course was complicated by refractory rejection, with graft loss occurring four weeks post-transplant. Figure 4 shows results of these measurements in a 28-year-old woman one to 33 days after renal transplantation.
During this time, the patient experienced one acute rejection episode, which was reversed with intravenous methylprednisolone therapy, and her graft function subsequently stabilized. Figure 5 compares the ratios of CyA plasma concentrations measured by HPLC with those measured by RIA at each study time of 2 h and 12 h during the course of treatment in the man described above.
Discussion
The extremely lipophilic and neutral nature of CyA, CyC, and CyD has allowed us to use an acid-base extraction technique to remove the ionizable acids and bases that had interfered with the assay when extraction was undertaken under neutral, acidic, or basic conditions alone.
With this extraction procedure, solvent programming We do, however, find it helpful to purge the system occasionally with acetonitrile to prevent accumulation on the column of (presumed) endogenous lipophilic materials.
Our results confirm the findings of Beveridge and his associates that the RIA overestimates the plasma concentrations of CyA determined by the more specific HPLC method, presumably because some, at least, of the metabolites of CyA cross react with the antibody. Such a discrepancy would be relatively unimportant if the results determined by each technique bore a constant relationship to each other, but we find, on the contrary, that differences in the ratios of concentrations within the same individual occur when samples are taken at different times after dosing and that there are considerable differences in ratios between individuals.
Preliminary evidence indicates that some of the variation results from differences in the elimination kinetics of CyA and its metabolites, and from a greater influence of renal dysfunction on the excretion of CyA metabolites than on the clearance of the parent CyA itself. We suspect also that concurrent administration of certain drugs may influence the ratio of CyA concentrations measured by HPLC to those measured by RIA; i.e., the metabolism of CyA may be accelerated or retarded, thereby altering the relative fraction of parent compound. Further studies are needed to explore these possibilities. The development of a therapeutic concentration range for parent CyA in plasma requires much greater experience in relating the measurements to patient outcomes. A comparison of the pharmacokinetic profiles developed by using both HPLC and RIA measurements will provide useful insights into these problems until specific assays for individual CyA metabolites become available. Some chromatographic peaks eluting within the first 15 mm ( Figure 1B ) probably represent CyA metabolites because these or similar peaks are commonly seen in patients receiving CyA but are not seen in blank plasmas or plasma samples to which standard amounts of CyA, CyC, and CyD have been added (Figures 1, A and C) . The purification of individual CyA metabolites may permit future qualitative identification of these peaks and their quantitative measurement, analyses that would be especially useful if one or more CyA metabolites are found to exert significant therapeutic or toxic effects.
Although there were variations in the relationships between CyA measurements by HPLC and by RIA at each of the study times, we have not observed any obvious trends with time ( Figure 5 ). In particular, there was no convincing evidence of accumulation of parent CyA or its (presumed) metabolites
